The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel
Conditions
Metastatic Lung Cancer - Metastatic Breast Cancer - Metastatic Gastric Cancer - Metastatic Prostate Cancer - Metastatic Bladder Cancer
Conditions: official terms
Lung Neoplasms - Neoplasm Metastasis
Conditions: Keywords
Docetaxel, Alpha 1 Acid Glycoprotein, Outcome
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Not yet recruiting
Summary
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.

One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein.

Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in cancer patients.

The investigators aim to prospectively study the association between the plasma level of alpha 1 acid glycoprotein and the outcome of docetaxel based therapy in cancer patients.
Detailed Description
Docetaxel based chemotherapy is a standard therapy in various metastatic cancers including non small cell lung cancer, breast cancer, gastric cancer, prostate cancer, and bladder cancer.

One of the main plasma protein carriers of docetaxel is Alpha 1 acid glycoprotein

Retrospective data suggests that plasma level of alpha 1 acid glycoprotein is associated with the outcome of docetaxel based therapy in non small cell lung cancer patients.

The investigators aim to prospectively study the association between the baseline plasma level of alpha 1 acid glycoprotein (measured on the first day of the first cycle of docetaxel) and the outcome (response rete, progression free survival, overall survival) of docetaxel based therapy in patients with metastatic non small cell lung cancer, breast cancer, stomach cancer, prostate cancer, and bladder cancer.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria

- patients with metastatic cancer from lung, breast, gastric, prostate, and bladder origin

- patients must be treated with docetaxel based chemotherapy

- patients must sign an informed consent form

Exclusion Criteria

- patients with metastatic cancer other than lung, breast, gastric, prostate, and bladder origin

- patients treated with chemotherapy other than docetaxel

- patients that did not sign an informed consent form
Location
Institute of Oncology, Meir Medical Center
Kfar-Saba, Israel
Status: Not yet recruiting
Start Date
April 2013
Completion Date
April 2018
Sponsors
Gottfried Maya
Source
Meir Medical Center
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page